IL-17F targeting biobetter (Abeome)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameIL-17F targeting biobetter (Abeome)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionInterleukin-17F modulators
TargetsInterleukin-17F
Therapy Area/IndicationsAutoimmune Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAbeome Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAbeome Corp
Active IndicationsN/A
Inactive IndicationsAutoimmune Diseases

Other Information

ATC CodeN/A
Related LinksN/A